STOCK TITAN

[Form 4] Rezolute, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Rezolute, Inc. (RZLT) – Form 4 insider transaction

Director Nerissa Kreher reported purchasing 3,076 common shares of Rezolute on 13 June 2025 at an average price of $3.25 per share. Following the transaction, Dr. Kreher directly owns 37,576 shares of the company’s common stock. No derivative securities were involved, and no dispositions were reported.

Rezolute, Inc. (RZLT) – Transazione interna Form 4

La direttrice Nerissa Kreher ha comunicato l'acquisto di 3.076 azioni ordinarie di Rezolute il 13 giugno 2025 a un prezzo medio di 3,25 $ per azione. Dopo la transazione, la Dott.ssa Kreher possiede direttamente 37.576 azioni del capitale sociale della società. Non sono stati coinvolti strumenti derivati e non sono state segnalate cessioni.

Rezolute, Inc. (RZLT) – Transacción interna Formulario 4

La directora Nerissa Kreher informó la compra de 3,076 acciones ordinarias de Rezolute el 13 de junio de 2025 a un precio promedio de $3.25 por acción. Tras la transacción, la Dra. Kreher posee directamente 37,576 acciones de las acciones comunes de la empresa. No se involucraron valores derivados y no se reportaron disposiciones.

Rezolute, Inc. (RZLT) – Form 4 내부자 거래

이사 Nerissa Kreher가 2025년 6월 13일에 Rezolute의 3,076 보통주를 주당 평균 $3.25에 매수했다고 보고했습니다. 거래 후 Kreher 박사는 회사 보통주를 직접 37,576주 보유하고 있습니다. 파생 증권은 포함되지 않았으며 처분 보고도 없었습니다.

Rezolute, Inc. (RZLT) – Transaction d’initié Formulaire 4

La directrice Nerissa Kreher a déclaré avoir acheté 3 076 actions ordinaires de Rezolute le 13 juin 2025 au prix moyen de 3,25 $ par action. Suite à cette transaction, le Dr Kreher détient directement 37 576 actions du capital social de la société. Aucune valeur dérivée n’a été impliquée et aucune cession n’a été rapportée.

Rezolute, Inc. (RZLT) – Insider-Transaktion Form 4

Direktorin Nerissa Kreher meldete den Kauf von 3.076 Stammaktien von Rezolute am 13. Juni 2025 zu einem durchschnittlichen Preis von 3,25 $ pro Aktie. Nach der Transaktion besitzt Dr. Kreher direkt 37.576 Aktien des Stammkapitals des Unternehmens. Es waren keine Derivate beteiligt und keine Veräußerungen wurden gemeldet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Minor insider purchase; signal is positive but immaterial to valuation.

Insider buying, even in small amounts, can indicate management confidence, yet the $10k value (~0.01% of market cap) keeps the market impact negligible. Ownership rises to 37,576 shares, but no change in control or strategic direction is implied. Investors might view the action favorably, though it does not meaningfully alter Rezolute’s capital structure or float.

Rezolute, Inc. (RZLT) – Transazione interna Form 4

La direttrice Nerissa Kreher ha comunicato l'acquisto di 3.076 azioni ordinarie di Rezolute il 13 giugno 2025 a un prezzo medio di 3,25 $ per azione. Dopo la transazione, la Dott.ssa Kreher possiede direttamente 37.576 azioni del capitale sociale della società. Non sono stati coinvolti strumenti derivati e non sono state segnalate cessioni.

Rezolute, Inc. (RZLT) – Transacción interna Formulario 4

La directora Nerissa Kreher informó la compra de 3,076 acciones ordinarias de Rezolute el 13 de junio de 2025 a un precio promedio de $3.25 por acción. Tras la transacción, la Dra. Kreher posee directamente 37,576 acciones de las acciones comunes de la empresa. No se involucraron valores derivados y no se reportaron disposiciones.

Rezolute, Inc. (RZLT) – Form 4 내부자 거래

이사 Nerissa Kreher가 2025년 6월 13일에 Rezolute의 3,076 보통주를 주당 평균 $3.25에 매수했다고 보고했습니다. 거래 후 Kreher 박사는 회사 보통주를 직접 37,576주 보유하고 있습니다. 파생 증권은 포함되지 않았으며 처분 보고도 없었습니다.

Rezolute, Inc. (RZLT) – Transaction d’initié Formulaire 4

La directrice Nerissa Kreher a déclaré avoir acheté 3 076 actions ordinaires de Rezolute le 13 juin 2025 au prix moyen de 3,25 $ par action. Suite à cette transaction, le Dr Kreher détient directement 37 576 actions du capital social de la société. Aucune valeur dérivée n’a été impliquée et aucune cession n’a été rapportée.

Rezolute, Inc. (RZLT) – Insider-Transaktion Form 4

Direktorin Nerissa Kreher meldete den Kauf von 3.076 Stammaktien von Rezolute am 13. Juni 2025 zu einem durchschnittlichen Preis von 3,25 $ pro Aktie. Nach der Transaktion besitzt Dr. Kreher direkt 37.576 Aktien des Stammkapitals des Unternehmens. Es waren keine Derivate beteiligt und keine Veräußerungen wurden gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KREHER NERISSA

(Last) (First) (Middle)
C/O REZOLUTE, INC.
275 SHORELINE DRIVE, SUITE 500

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rezolute, Inc. [ RZLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/13/2025 P 3,076 A $3.25 37,576 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nerissa Kreher 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rezolute (RZLT) shares did the insider buy?

3,076 common shares were purchased.

What price did Director Nerissa Kreher pay per share?

The reported purchase price was $3.25 per share.

What is the insider’s total ownership after the transaction?

Dr. Kreher now directly owns 37,576 RZLT shares.

Were any derivative securities involved in this Form 4 filing?

No; the filing lists no derivative transactions.

Is this Form 4 likely to materially affect Rezolute’s stock price?

Given the small dollar value (~$10k), the filing is considered immaterial to the company’s valuation.
Rezolute Inc

NASDAQ:RZLT

RZLT Rankings

RZLT Latest News

RZLT Latest SEC Filings

RZLT Stock Data

349.86M
78.35M
13.48%
81.95%
3.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY